Items per page

Search results

Items: 1 to 20 of 153

Search results: x Variables, w Analyses, x Documents, and z Datasets in x Studies
Clinical VariableDatasetVariable DescriptionVariable ID
This sample attributes data table includes sample analyte type (DNA or RNA), disease state of sample (tumor or normal/in remission), and sample type obtained from subjects in the Rhabdoid Tumor (RT) substudy. The variable, DISEASEPROJECT, is included to track the disease project of the sample.
Extract namephv00167664.v4.p7
The data table contains Neuroblastoma (NBL) subject phenotypes including sociodemography (n=4 variables; age, gender, ethnicity and race), COG risk score and protocol (n=2 variables), sequence of events (n=4 variables), tumor classification (n=9 variables; INSS stage, MYCN and ploidy status, INPC or Shimada prognostic factor, grade of neuroblastic differentiation, mitosis-karyorrhexis index (MKI) and diagnostic category, and icdo and snowmed topography code and description), and specimen quality (n=2 variables; percent tumor and percent necrosis).
Either the ICDO code, or the SNOMED code (if ICDO=999 or Unknown) or a Hard-coded value if both codes unknown but information availablephv00167632.v10.p7
This sample attributes data table includes sample analyte type (DNA or RNA), disease state of sample (tumor or normal/in remission), and sample type obtained from subjects in the Wilms' Tumor (WT) substudy. The variable, DISEASEPROJECT, is included to track the disease project of the sample.
Analyte typephv00167673.v7.p7
This sample attributes data table includes sample analyte type (DNA or RNA), disease state of sample (tumor or normal/in remission), and sample type obtained from subjects in the Wilms' Tumor (WT) substudy. The variable, DISEASEPROJECT, is included to track the disease project of the sample.
Disease state of samplephv00167670.v7.p7
The data table contains Neuroblastoma (NBL) subject phenotypes including sociodemography (n=4 variables; age, gender, ethnicity and race), COG risk score and protocol (n=2 variables), sequence of events (n=4 variables), tumor classification (n=9 variables; INSS stage, MYCN and ploidy status, INPC or Shimada prognostic factor, grade of neuroblastic differentiation, mitosis-karyorrhexis index (MKI) and diagnostic category, and icdo and snowmed topography code and description), and specimen quality (n=2 variables; percent tumor and percent necrosis).
Diagnostic Category (Revised INPC). If INPC diagnostic category is missing, then this is Shimada diagnostic category.phv00167629.v10.p7
This sample attributes data table includes sample analyte type (DNA or RNA), disease state of sample (tumor or normal/in remission), and sample type obtained from subjects in the Cell Lines and Xenografts (PPTP - Pediatric Preclinical Testing Program) substudy. The variable, DISEASEPROJECT, is included to track the disease project of the sample.
Extract namephv00167657.v6.p7
The data table contains Neuroblastoma (NBL) subject phenotypes including sociodemography (n=4 variables; age, gender, ethnicity and race), COG risk score and protocol (n=2 variables), sequence of events (n=4 variables), tumor classification (n=9 variables; INSS stage, MYCN and ploidy status, INPC or Shimada prognostic factor, grade of neuroblastic differentiation, mitosis-karyorrhexis index (MKI) and diagnostic category, and icdo and snowmed topography code and description), and specimen quality (n=2 variables; percent tumor and percent necrosis).
Number of days from diagnosis until the event, or until last contact if no eventphv00167635.v10.p7
This sample attributes data table includes sample analyte type (DNA or RNA), disease state of sample (tumor or normal/in remission), and sample type obtained from subjects in the Osteosarcoma (OS) substudy. The variable, DISEASEPROJECT, is included to track the disease project of the sample.
Sample typephv00167651.v9.p7
The data tables contains Cell Lines and Xenografts (PPTP - Pediatric Preclinical Testing Program) subject phenotypes including gender (n=1 variable). The complete dataset has not been submitted, so more data is forthcoming.
Genderphv00167654.v5.p7
The data table contains the gender variable of Wilms' Tumor (WT) subjects.
TARGET Subject Idphv00167667.v6.p7
This sample attributes data table includes sample analyte type (DNA or RNA), disease state of sample (tumor or normal/in remission), and sample type obtained from subjects in the Osteosarcoma (OS) substudy. The variable, DISEASEPROJECT, is included to track the disease project of the sample.
Sample Namephv00167648.v9.p7
This sample attributes data table includes sample analyte type (DNA or RNA), disease state of sample (tumor or normal/in remission), and sample type obtained from subjects in the Neuroblastoma (NBL) substudy. The variable, DISEASEPROJECT, is included to track the disease project of the sample.
Analyte typephv00167645.v11.p7
The data table contains Neuroblastoma (NBL) subject phenotypes including sociodemography (n=4 variables; age, gender, ethnicity and race), COG risk score and protocol (n=2 variables), sequence of events (n=4 variables), tumor classification (n=9 variables; INSS stage, MYCN and ploidy status, INPC or Shimada prognostic factor, grade of neuroblastic differentiation, mitosis-karyorrhexis index (MKI) and diagnostic category, and icdo and snowmed topography code and description), and specimen quality (n=2 variables; percent tumor and percent necrosis).
Age at diagnosisphv00167619.v10.p7
This sample attributes data table includes sample analyte type (DNA or RNA), disease state of sample (tumor or normal/in remission), and sample type obtained from subjects in the Neuroblastoma (NBL) substudy. The variable, DISEASEPROJECT, is included to track the disease project of the sample.
Disease state of samplephv00167642.v11.p7
This sample attributes data table includes sample analyte type (DNA or RNA), disease state of sample (tumor or normal/in remission), and sample type obtained from subjects in the Osteosarcoma (OS) substudy. The variable, DISEASEPROJECT, is included to track the disease project of the sample.
Disease projectphv00196460.v6.p7
The data table contains Neuroblastoma (NBL) subject phenotypes including sociodemography (n=4 variables; age, gender, ethnicity and race), COG risk score and protocol (n=2 variables), sequence of events (n=4 variables), tumor classification (n=9 variables; INSS stage, MYCN and ploidy status, INPC or Shimada prognostic factor, grade of neuroblastic differentiation, mitosis-karyorrhexis index (MKI) and diagnostic category, and icdo and snowmed topography code and description), and specimen quality (n=2 variables; percent tumor and percent necrosis).
Revised INPC prognostic group (Cancer 2003). If INPC is missing, this is the Shimada classification (JNCI 1984).phv00167626.v10.p7
The data table contains the gender variable of Rhabdoid Tumor (RT) subjects.
Genderphv00167661.v4.p7
The data table contains Neuroblastoma (NBL) subject phenotypes including sociodemography (n=4 variables; age, gender, ethnicity and race), COG risk score and protocol (n=2 variables), sequence of events (n=4 variables), tumor classification (n=9 variables; INSS stage, MYCN and ploidy status, INPC or Shimada prognostic factor, grade of neuroblastic differentiation, mitosis-karyorrhexis index (MKI) and diagnostic category, and icdo and snowmed topography code and description), and specimen quality (n=2 variables; percent tumor and percent necrosis).
COG Protocol number on which the patient was enrolled [901=Trial of mouse monoclonal Anti-GD-2 antibody 14.G2A plus IL-2 with or without GM-CSF in children with refractory NBL or melanoma; 911=I-131-MIBG for therapy of advanced neuroblastoma; 914=A dose escalation study of cisplatin, doxorubicin, VP-16, and ifosfamide followed by GM-CSF in advanced NBL and peripheral neuroepithelioma; 925=Study of topotecan; 935=Study of ch14.18 with GM-CSF in children with NBL and other GD2 positive malignancies immediately post ABMT or PBSC; 937=Phase I trial of ZD1694, an inhibitor of thymidylate synthase, in pediatric patients with advanced neoplastic disease; 9709=A phase I study of fenretinide in children with high risk solid tumors; 321P2=New intensive chemotherapy for CCG stage II (with N-myc amplification), stage III and stage IV neuroblastoma; 321P3=Treatment of poor prognosis neuroblastoma before disease progression with intensive multimodal therapy and BMT; 323P=Cyclic combination chemotherapy for newly diagnosed stage III neuroblastoma age 2 and older and stage IV Nneuroblastoma all ages; 3881=Biology and therapy of good, intermediate, and selected poor prognosis neuroblastoma; 3891=Conventional dose chemoradiotherapy vs ablative chemoradiotherapy with autologous BMT for high-risk neuroblastoma; 3951=Phase I pilot study of multiple cycles of high dose chemotherapy with peripheral blood stem cell infusions in advanced stage neuroblastoma.; 4941=National Wilms tumor study V - therapeutic trial & biology study; 8605=Study of the combination of ifosfamide, mesna, and VP-16 in children and young adults with recurrent sarcomas, PNET and other tumors; 8742=Phase III portion of 8741 for neuroblastoma; 9047=Neuroblastoma biology protocol; 9082=Protocol for the development of intervention strategies to reduce the time between symptom onset and diagnosis of childhood cancer -a pediatric oncology group cancer control study; 9140=Therapy for patients with recurrent or refractory neuroblastoma - a phase II study; 9262=A Phase II study of taxol in children with recurrent/refractory soft-tissue sarcoma, rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma, neuroblastoma, germ cell tumors, Wilms' tumor, hepatoblastoma, and hepatocellular carcinoma, a POG study; 9280=Neuroblastoma epidemiology protocol - A Non-Therapeutic Study - A Joint Project of: The University of North Carolina, The Pediatric Oncology Group and The Children's Cancer Study Group; 9340=Treatment of patients >365 days at diagnosis with stage IV NBL: Upfront Phase II Window - A Phase II Study; 9341=Treatment of patients >365 days at diagnosis with stage IV and stage IIB/III (N-myc) NBL - a phase III study; 9342=Neuroblastoma #5, bone marrow transplant - a phase III study; 9343=Interleukin-6 in children receiving autologous bone marrow transplantation for advanced neuroblastoma - a pediatric oncology group phase I trial; 9361=Topotecan in pediatric patients with recurrent or progressive solid tumors - a pediatric oncology group phase II study; 9375=Topotecan plus cyclophosphamide in children with solid tumors - a pediatric oncology group phase I trial; 9464=Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors - a pediatric oncology group phase II study; 9640=Treatment of patients with high risk neuroblastoma (a feasibility pilot) using two cycles of marrow ablative chemotherapy followed by rescue With peripheral blood stem cells (PBSC), radiation therapy; A3973=A randomized study of purged vs. unpurged PBSC transplant following dose intensive induction therapy for high risk NBL; AADM01P1=Protocol for registration and consent to the childhood cancer research network: a limited institution pilot; AAML00P2=A dose finding study of the safety of gemtuzumab ozogamicin combined with conventional chemotherapy for patients with relapsed or refractory acute myeloid leukemia; ACCL0331=A Randomized double blind placebo controlled clinical trial to assess the efficacy of traumeelĀ® S (IND # 66649) for the prevention and treatment of mucositis in children undergoing hematopoietic stem cell transplantation; ACCRN07=Protocol for the enrollment on the official COG registry, The Childhood Cancer Research Network (CCRN); ADVL0018=Phase I study of hu14.18-IL2 fusion protein in patients with refractory neuroblastoma and other refractory GD2 expressing tumors; ADVL0212=A Phase I study of depsipeptide (NSC#630176, IND# 51810) in pediatric patients with refractory solid tumors and leukemias; ADVL0214=A phase I study of single agent OSI-774 (Tarceva) (NSC # 718781, IND #63383) followed by OSI-774 with temozolomide for patients with selected recurrent/refractory solid tumors, including brain tumors; ADVL0215=A phase I study of decitabine in combination with doxorubicin and cyclophosphamide in the treatment of relapsed or refractory solid tumors; ADVL0421=A phase II study of oxaliplatin in children with recurrent solid tumors; ADVL0524=Phase II trial of ixabepilone (BMS-247550), an epothilone B analog, in children and young adults with refractory solid tumors; ADVL0525=A phase II study of pemetrexed in children with recurrent malignancies; ADVL06B1=A pharmacokinetic-pharmacodynamic-pharmacogenetic study of actinomycin-D and vincristine in children with cancer; ADVL0714=A phase I study of VEGF trap (NSC# 724770, IND# 100137) in children with refractory solid tumors; ALTE03N1=Key adverse events after childhood cancer; ALTE05N1=Umbrella long-term follow-up protocol; ANBL0032=Phase III randomized study of chimeric antibody 14.18 (Ch14.18) in high risk neuroblastoma following myeloablative therapy and autologous stem cell rescue; ANBL00B1=Neuroblastoma biology studies; ANBL00P1=A pilot study of tandem high dose chemotherapy with stem cell rescue following induction therapy in children with high risk neuroblastoma; ANBL02P1=A pilot induction regimen incorporating dose-intensive topotecan and cyclophosphamide for treatment of newly diagnosed high risk neuroblastoma; ANBL0321=Phase II study of fenretinide in pediatric patients with resistant or recurrent neuroblastoma; ANBL0322=A phase II study of hu14.18-IL2 (BB-IND-9728) in children with recurrent or refractory neuroblastoma; ANBL0532=Phase III randomized trial of single vs. tandem myeloablative as consolidation therapy for high-risk neuroblastoma; ANBL0621=A phase II study of ABT-751, an orally bioavailable tubulin binding agent, in children with relapsed or refractory neuroblastoma; B003=Diagnostic & prognostic studies in NBL; B903=Childhood cancer genetics; B947=Protocol for collection of biology specimens for research studies; B954=Opsoclonus-myoclonus-ataxia syndrome, neuroblastoma and the presence of anti-neuronal antibodies; B973=Laboratory-clinical studies of neuroblastoma; E04=Self-administered epidemiology questionnaire; E18=A case-control study of risk factors for neuroblastoma; I03=Neuroblastoma, diagnostic/prognostic; N891=Parents' perceptions of randomization; P9462=Randomized treatment of recurrent neuroblastoma with topotecan regimens following desferrioxamine (POG only) in an investigational window; P9641=Primary surgical therapy for biologically defined low-risk neuroblastoma; P9761=A phase II trial of irinotecan in children with refractory solid tumors; P9963=A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors; R9702=Prognostic implications of MIBG uptake in patients with neuroblastoma previously treated on CCG-3891; S31=Right atrial catheter study; S921=Comparison of urokinase vs heparin in preventing Infection in central venous devices in children with malignancies]phv00167638.v10.p7
This sample attributes data table includes sample analyte type (DNA or RNA), disease state of sample (tumor or normal/in remission), and sample type obtained from subjects in the Neuroblastoma (NBL) substudy. The variable, DISEASEPROJECT, is included to track the disease project of the sample.
Sample Namephv00167641.v11.p7
This sample attributes data table includes sample analyte type (DNA or RNA), disease state of sample (tumor or normal/in remission), and sample type obtained from subjects in the Neuroblastoma (NBL) substudy. The variable, DISEASEPROJECT, is included to track the disease project of the sample.
Sample typephv00167644.v11.p7
Items per page

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk